FY2023 Earnings Forecast for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Issued By Cantor Fitzgerald

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Analysts at Cantor Fitzgerald lifted their FY2023 earnings per share (EPS) estimates for X4 Pharmaceuticals in a research report issued on Monday, May 22nd. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($0.64) per share for the year, up from their previous estimate of ($0.76). Cantor Fitzgerald currently has a “Overweight” rating and a $3.00 target price on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.65) per share.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) last released its quarterly earnings results on Tuesday, March 21st. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06).

Several other research firms also recently weighed in on XFOR. HC Wainwright cut their price target on X4 Pharmaceuticals from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, March 22nd. Oppenheimer decreased their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday, March 24th. Stifel Nicolaus raised their price target on X4 Pharmaceuticals from $4.00 to $5.00 in a report on Wednesday, May 17th. Finally, B. Riley decreased their price target on X4 Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, April 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $3.50.

X4 Pharmaceuticals Stock Down 4.4 %

Shares of NASDAQ:XFOR opened at $1.97 on Wednesday. X4 Pharmaceuticals has a 52-week low of $0.65 and a 52-week high of $2.41. The firm has a market capitalization of $240.75 million, a P/E ratio of -1.50 and a beta of 0.70. The stock has a 50 day moving average price of $1.30 and a 200-day moving average price of $1.20. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.04 and a current ratio of 5.04.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of XFOR. JPMorgan Chase & Co. boosted its position in X4 Pharmaceuticals by 423.5% in the 1st quarter. JPMorgan Chase & Co. now owns 626,047 shares of the company’s stock valued at $545,000 after buying an additional 506,449 shares during the period. Perceptive Advisors LLC purchased a new position in X4 Pharmaceuticals in the 1st quarter valued at approximately $3,955,000. Geode Capital Management LLC boosted its position in X4 Pharmaceuticals by 88.7% in the 1st quarter. Geode Capital Management LLC now owns 1,108,684 shares of the company’s stock valued at $965,000 after buying an additional 521,168 shares during the period. Schonfeld Strategic Advisors LLC boosted its position in X4 Pharmaceuticals by 15.8% in the 1st quarter. Schonfeld Strategic Advisors LLC now owns 1,037,000 shares of the company’s stock valued at $902,000 after buying an additional 141,700 shares during the period. Finally, AXA S.A. boosted its position in X4 Pharmaceuticals by 0.8% in the 1st quarter. AXA S.A. now owns 4,396,468 shares of the company’s stock valued at $3,825,000 after buying an additional 34,827 shares during the period. Institutional investors and hedge funds own 56.46% of the company’s stock.

About X4 Pharmaceuticals

(Get Rating)

X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.